Cabozantinib as a novel therapy for renal cell carcinoma.
Vaishampayan U.
Curr Oncol Rep · journal article · DOI 10.1007/s11912-012-0289-x PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cabozantinib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
20 träffarExpression and clinical relevance of MET and ALK in Ewing sarcomas.
Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM.
Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.28047Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D, Temraz S, Wehbe D, Shamseddine A.
Crit Rev Oncol Hematol · review; journal article · DOI 10.1016/j.critrevonc.2013.01.002Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.
Hart CD, De Boer RH.
Onco Targets Ther · review-article; journal article · DOI 10.2147/ott.s27671Cabozantinib approved for advanced medullary thyroid cancer.
Traynor K.
Am J Health Syst Pharm · news · DOI 10.2146/news130005Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.
Lee RJ, Smith MR.
Cancer J · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1097/ppo.0b013e318281e280From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT, Carducci MA.
Cancer J · review; journal article · DOI 10.1097/ppo.0b013e31827e0b86Cabozantinib in prostate cancer: the beginning of a precision paradigm?
Goodin S, DiPaola RS.
J Clin Oncol · comment; editorial · DOI 10.1200/jco.2012.46.6185Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.
J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2012.45.0494Cabozantinib for the treatment of advanced medullary thyroid cancer.
Nagilla M, Brown RL, Cohen EE.
Adv Ther · comparative study; review; journal article · DOI 10.1007/s12325-012-0060-6Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM.
Cancer Discov · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-11-0240Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Bowles DW, Kessler ER, Jimeno A.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2011.47.11.1688487Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-11-0264Multikinase inhibitors: a new option for the treatment of thyroid cancer.
Gild ML, Bullock M, Robinson BG, Clifton-Bligh R.
Nat Rev Endocrinol · review; journal article · DOI 10.1038/nrendo.2011.141Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ, Lee RJ, Smith MR.
J Clin Oncol · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.2010.34.4994VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM.
Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-10-2527Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R.
J Clin Oncol · research-article; clinical trial, phase i; journal article · DOI 10.1200/jco.2010.32.4145XL184 (cabozantinib) for medullary thyroid carcinoma.
Durante C, Russo D, Verrienti A, Filetti S.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2011.559163Management of medullary thyroid cancer.
Ball DW.
Minerva Endocrinol · review; journal articleXL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.
Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R.
IDrugs · research-article; review; journal article